Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Solve a Mystery about Type 2 Diabetes Drug

Published: Friday, November 22, 2013
Last Updated: Friday, November 22, 2013
Bookmark and Share
AB SCIEX TripleTOF® and QTRAP® technologies support breakthrough medical study.

Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX played a critical role in the analysis that led to this breakthrough finding.  The research is published in this month’s issue of the journal Nature Medicine.  

Doctors have known for decades that metformin helps treat type 2 diabetes.  However, questions had lingered for more than 50 years whether this drug, which is available as a generic drug, worked to lower blood glucose in patients by directly working on the glucose. People with type 2 diabetes have high blood sugar levels and have trouble converting sugar in their blood into energy because of low levels of insulin. For treating this condition, metformin is considered the most widely prescribed anti-diabetic drug in the world.  

Until now, no one had been able to explain adequately how this drug lowers blood sugar. According to this new study, the drug works by reducing harmful fat in the liver. People who take metformin reportedly often have a fatty liver, which is frequently caused by obesity.  

“Fat is likely a key trigger for pre-diabetes in humans,” said Professor Bruce Kemp, PhD, the Head of Protein Chemistry and Metabolism at St. Vincent’s Institute of Medical Research.  “Our study indicates that metformin doesn’t directly reduce sugar metabolism, as previously suspected, but instead reduces fat in the liver, which in turn allows insulin to work effectively.”  

The breakthrough in pinning down how the drug functions began with the researchers making genetic mutations to the genes of two enzymes, ACC1 and ACC2, in mice, so they could no longer be controlled.  What happened next surprised the researchers: the mice didn’t get fat as expected, but Associate Professor Gregory Steinberg, PhD at McMaster University noticed that the mice had fatty livers and a pre-diabetic condition. Then the researchers put the mice on a high fat diet and they became fat, while metformin did not lower the blood sugar levels of the mutant mice. 

The findings are expected to help researchers better directly target the condition, which affects over 100 million people around the world, according to published reports. It is also believed that with the mystery of metformin solved, the application of the drug could go beyond just diabetes and potentially be used to treat other medical conditions. 

“AB SCIEX mass spectrometry solutions help researchers explore big questions and conduct breakthrough studies, such as this remarkable type 2 diabetes study,” said Rainer Blair, President of AB SCIEX.   “In order to understand disease at the molecular level, researchers need the sensitive detection and reproducible quantitation provided by AB SCIEX tools. We enable the research community to solve biological mysteries and rethink the possibilities to transform health.”

For the research conducted by the Australian and Canadian researchers, the analysis at the molecular level was optimized on AB SCIEX instrumentation, including the AB SCIEX TripleTOF® 5600 and the AB SCIEX QTRAP® 5500 system.  The TripleTOF system, with its high-speed, high-quality MS/MS capabilities, was used for the discovery of key proteins and phosphopeptides.  The QTRAP system, with its high sensitivity MRM (multiple reaction monitoring) capabilities, was used for quantitation of metabolites, including nucleotides and malonyl-CoA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCIEX, QPS Holdings Collaborate
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification.
Wednesday, April 06, 2016
SCIEX, Children's Medical Research Institute Collaborate
SCIEX industrialized proteomics solutions, using SWATH® Acquisition-based workflows and powered by the OneOmics™ Project, will enable large scale proteome studies to advance cancer research.
Thursday, February 11, 2016
SCIEX, A*STAR’s BTI Launch Collaboration
Agreement aims to boost innovation of protein drugs that target new diseases and are safer for patients.
Wednesday, January 27, 2016
SCIEX, Pressure BioSciences Partner
SCIEX and Pressure BioSciences to offer complete solution for next-generation proteomics, to increase the reproducibility and depth of proteomic analysis.
Wednesday, January 13, 2016
SCIEX, University of Manchester Partner
SWATH® Acquisition-based next-generation proteomics technology promises to make industrial proteomics a reality.
Thursday, October 29, 2015
SCIEX Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center
Collaboration targets research reproducibility crisis with highly validated multiplex quantitation assays.
Wednesday, September 23, 2015
SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
SCIEX and New Objective Partner
Partnership will provide advanced nanospray ionization technologies for next-generation proteomics.
Tuesday, May 26, 2015
SCIEX and Hepregen Announce Co-Marketing Agreement
Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.
Friday, May 22, 2015
Sciex, Hepregen Team up on Metabolite Identification Offering
This recently announced collaboration aims to provide practical solutions for drug metabolism researchers.
Thursday, May 21, 2015
Dr. Gyula Vigh wins Arnold O. Beckman Award
SCIEX sponsored award recognizes outstanding contributions to the field of electrodriven separation techniques.
Thursday, May 07, 2015
SCIEX and Mass Consortium Corporation Announce Exclusive Reseller Agreement
SCIEX to provide customers with XCMSplus software solution for simplified and accelerated metabolomics workflows.
Tuesday, March 31, 2015
SCIEX Announces OneOmics™ Collaborators
Advaita Bioinformatics, Researchers at Yale University and ISB launch applications and libraries that combine next-generation proteomics and next-generation sequencing data in innovative ways.
Thursday, March 19, 2015
SCIEX and Labor Berlin Collaboration to Advance Forensic Testing
Collaboration for the development of a hybrid Quadrupole Time-of-Flight (TOF) MS/MS reference library.
Thursday, March 05, 2015
New Capabilities for Bioanalysis Studies at the International Pharmaceutical Research Center
AB SCIEX Triple Quad™ 6500 LC/MS/MS systems enable new levels of sensitivity for clinical trials of inhaled drugs.
Wednesday, February 11, 2015
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!